Pfizer Inc.
on Wednesday raised estimates for the sale of Covid-19 vaccine developed with German Bionech of 28.8% to $ 33.5 billion, when countries scramble supply of shots.
The company said the estimate of increased vaccine sales was based on the supply signed for 2.1 billion dose this year, and could increase if signing an additional contract.
Pfizer and Bionth hope to produce 3 billion vaccine doses this year.
Pfizer gets early in December with an emergency authorization A.S.
First of the Covid-19 vaccine, and since then jumped before the rival that faced manufacturing obstacles.
Johnson & Johnson vaccine is also under supervision of security issues.
J & J last week estimated that the sales of Covid-19-19-year vaccine was full of $ 2.5 billion, while Modera had estimated $ 19.2 billion.
Pfizer said it believed that the third dose of “booster” from the vaccine would be needed in the future, which could help produce more sales in 2022.
The company said on Wednesday it could submit an emergency use permit for a potential booster dose in early August.
Infectious diseases of Anthony Fauci Fauci said on Sunday that Americans who compromised immunity can end up needing a booster shot because the United States is related to the increasing case of the Delta variant of Coronavirus.
The United States bought 200 million doses of Pfizer / Biontech vaccine last week to help with child vaccination and the possibility of a booster shot – if needed.
Previous Pfizer forecasts in May of $ 26 billion was based on a signed agreement of 1.6 billion doses.
Wall Street is widely in line with that estimate for $ 28.51 billion, according to nine analysts surveyed by refinitiv.
Expenditures and profits from vaccines are divided into 50-50 between Pfizer and Bionth.